US Patent

US10709713 — Nanoparticulate meloxicam formulations

Method of Use · Assigned to Baudax Bio Inc · Expires 2030-05-26 · 4y remaining

Vulnerability score 56/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects nanoparticulate compositions of meloxicam, a drug listed against Mobic, with an average particle size of less than about 2000 nm.

USPTO Abstract

The present invention is directed to nanoparticulate compositions comprising meloxicam particles having an effective average particle size of less than about 2000 nm.

Drugs covered by this patent

Mobic (MELOXICAM) · Boehringer Ingelheim

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2750`	—	Mobic

Patent Metadata

Patent number: US10709713
Jurisdiction: US
Classification: Method of Use
Expires: 2030-05-26
Drug substance claim: No
Drug product claim: No
Assignee: Baudax Bio Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.